JPRN-UMIN000003164已完成未知
A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the patient with advanced colorectal cancer - A feasibility study of adjuvant XELOX therapy for the patient with advanced colorectal cancer
Osaka Medical Center for Cancer and Cardiovascular Diseases0 个研究点目标入组 25 人开始时间: 2010年2月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 2) Pregnant or breast-feeding women 3) Severe mental disease 4) Systemic administration of corticosteroids 5) Continuous medication of flusitosine, fenitoin,and/or Warfarin 6) Other severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, regular use of insulin or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 7) Myocardial infarction within the past 6 months 8) Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
已完成
2 期
Effect of ciprofloxacin on advanced chronic periodontitissever chronic periodontitis.Chronic periodontitis Chronic pericoronitisIRCT2017061734582N1zahdan university of medical siences80
招募中
不适用
A feasibility study of neoadjuvant chemotherapy with mFOLFOX6 in patients with locally metastatic rectal cancerrectal cancerJPRN-UMIN000003428Toho University school of medicine20
已完成
不适用
A feasibility study of neoadjuvant chemotherapy with docetaxel+cisplatin+capecitabine (DCX) for HER2-negative gastric cancer with macroscopic type 4 and large type 3, or with multiple lymph node metastasisGastric cancerJPRN-UMIN000026783agoya University20
已完成
不适用
Feasibility study of neoadjuvant chemotherapy with docetaxel/CDGP/5-fluorouracil in resectable esophagus canceresophagus cancerJPRN-UMIN000014305Department of Medical Oncology, Sapporo Medical University School of Medicine28
进行中（未招募）
1 期
eo-adjuvant pembrolizumab in primary stage IV ovarian cancerEUCTR2016-004700-56-NLKI-AV30